Abstracts Archive - Page 1160 of 2607 - ACR Meeting Abstracts

Abstract Number: 359 • 2019 ACR/ARP Annual Meeting
Impact of Hospital Admissions on Adherence to Allopurinol Therapy After Discharge
Nicholas Lebedoff¹, Andrea Barker ², Curry L. Koening ³, Trevor Jones ⁴, Richard Rose ⁴, Peter Yarbrough ⁴ and Michael Battistone ⁵, ¹University of Utah, Salt Lake City, ²Salt Lake City Veterans Affairs Medical Center & University of Utah, North Salt Lake, UT, ³University of Utah Hospital, Salt Lake City, UT, ⁴Salt Lake City Veterans Affairs Medical Center & University of Utah, Salt Lake City, ⁵Salt Lake City Veterans Affairs Medical Center & University of Utah, Salt Lake City, UT
Background/Purpose: Gout is a common disease with effective medical therapies, yet many cases are complicated by providers’ hesitancy to prescribe an adequate dose of urate-lowering…
Abstract Number: 360 • 2019 ACR/ARP Annual Meeting
Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol Is Very Cost Effective: A Health Economic Analysis
Philip Robinson¹, Nicola Dalbeth ² and Peter Donovan ³, ¹University of Queensland, Brisbane, Queensland, Australia, ²University of Auckland, Auckland, New Zealand, ³University of Queensland, HERSTON, Australia
Background/Purpose: Prophylaxis of acute gout flares when commencing urate lowering therapy is recommended by international guidelines. Whether this is a cost-effective intervention is currently unknown.…
Abstract Number: 361 • 2019 ACR/ARP Annual Meeting
Frequency of Allopurinol Dose Reduction in Hospitalized Patients with Gout Flares
Irvin Huang¹, Alison Bays ² and Jean Liew ³, ¹University of Washington - Boise Internal Medicine Residency, Boise, ID, ²University of Washington Division of Rheumatology, Seattle, WA, ³University of Washington, Seattle, WA
Background/Purpose: It is a common misconception that allopurinol should either be held or reduced during gout flares and renal insufficiency. However, current guidelines recommend the…
Abstract Number: 362 • 2019 ACR/ARP Annual Meeting
Methods to Efficiently Recruit Minority Patients with Gout for Clinic-Based Registries
Giovanni Adami¹, Giovanna Rosas ², Joshua Melnick ³, Jeffrey Foster ², Elizabeth Rahn ², Amy Mudano ⁴, Jeffrey Curtis ², Tony Merriman ⁵, S Louis Bridges ⁴ and Kenneth Saag ², ¹University of Verona, Verona, Italy, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmimgham, AL, ⁴University of Alabama at Birmingham, Birmingham, ⁵University of Otago, Birmingham, AL
Background/Purpose: Gout is frequently misdiagnosed and/or miscoded, making approaches to identifying eligible patients for observational and interventional studies more challenging. Ethnic and racial minorities are…
Abstract Number: 363 • 2019 ACR/ARP Annual Meeting
Efficacy and Outcomes of Telephone-Based Management Program in Patients with Gout
Abdalhamid Al Harash¹, Tarun Sharma ¹, Brenda Dunmire ², Mary Chester Wasko ³ and William Ayoub ¹, ¹Allegheny Health Network, Pittsburgh, PA, ²AHN, Pittsburgh, PA, ³Allegheny Health Network-West Penn Hospital, Pittsburgh, PA
Background/Purpose: Gout is the most common inflammatory arthritis in the US, and causes significant morbidity. Despite published guidelines and available effective treatment, management remains suboptimal,…
Abstract Number: 364 • 2019 ACR/ARP Annual Meeting
Calcium Pyrophosphate Crystal Arthritis During Hospitalizations: A Prospective, Crystal-Proven Case Series
Laura Ranieri¹, Francisca Sivera ² and Mariano Andrés ³, ¹Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ²Hospital General Universitario de Elda, Elda, Spain, ³Hospital General Universitario de Alicante-ISABIAL, Universidad Miguel Hernández, Alicante, Spain
Background/Purpose: Despite more than fifty years after its initial description, key questions for calcium pyrophosphate (CPP) crystal disease, such as clinical spectrum, diagnosis or management…
Abstract Number: 365 • 2019 ACR/ARP Annual Meeting
Classifying Pseudogout Using Machine Learning Approaches with Electronic Health Record Data
Sara K. Tedeschi¹, Tianrun Cai ², Zeling He ³, Yuri Ahuja ⁴, Chuan Hong ⁵, Katherine Yates ⁴, Kumar Dahal ², Chang Xu ³, Houchen Lyu ², Kazuki Yoshida ⁶, Daniel Solomon ⁷, Tianxi Cai ⁵ and Katherine Liao ², ¹Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Boston, ⁵Harvard T.H. Chan School of Public Health, Boston, ⁶Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, ⁷Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Identifying pseudogout in large administrative datasets has been difficult due to lack of specific billing codes for this acute subtype of calcium pyrophosphate (CPP)…
Abstract Number: 366 • 2019 ACR/ARP Annual Meeting
Serum Uric Acid Level and Subclinical Coronary Atherosclerosis in Asymptomatic Individuals: An Observational Cohort Study
Doo-Ho Lim¹, Gyung-Min Park ², Seung Won Choi ³, Su Jin Choi ⁴, So Hye Nam ⁵, Seokchan Hong ⁴, Yong-Gil Kim ⁴, Chang-Keun Lee ⁴ and Bin Yoo ⁴, ¹Division of Rheumatology, Department of Internal Medicine, Ulsan University Hospital, Ulsan, Republic of Korea, ²Ulsan University hospital, Ulsan, Republic of Korea, ³Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea, Ulsan, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, ⁵Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: High serum uric acid (SUA) level is the main prerequisite for gout, and it might be associated with obesity, hypertension, glucose intolerance, insulin resistance,…
Abstract Number: 367 • 2019 ACR/ARP Annual Meeting
Understanding the Mystery of Sarcoidosis: An Academic Rheumatology Center Experience
Madiha Tariq¹, Mamatha Katikaneni ², Kanchan Malhotra ³, Jerry McLarty ¹, Sarwat Umer ⁴ and Samina Hayat ⁵, ¹LSUHSC - Shreveport, Shreveport, ²LSUHSC- Shreveport, Shreveport, LA, ³LSUHSC - Shreveport, Shereveport, ⁴LSUHSC- Shreveport, Shreveport, ⁵LSUHSC- Shreveport, Shreveport
Background/Purpose: Sarcoidosis is an inflammatory disorder of unknown etiology characterized by tissue infiltration with non-caseating granulomas which can affect any organ. The most common organ…
Abstract Number: 368 • 2019 ACR/ARP Annual Meeting
Practice Patterns in Bone Health and Vitamin D Management in Sarcoidosis: A Survey of Physicians Who Manage Sarcoidosis
Huzaefah Syed¹, Thieroff George ², Thomas Iden ¹, Aamer Syed ¹, Alicia Gerke ³ and Trang Le ¹, ¹VCU Medical Center, Richmond, VA, ²VCU Medical Center, Richmond, VA, ³University of Iowa, Iowa City, IA
Background/Purpose: Sarcoidosis is a multisystem disease caused by granulomatous inflammation of unclear etiology. Hypercalcemia, seen in 2-30% of patients with sarcoidosis, is caused by calcitriol…
Abstract Number: 369 • 2019 ACR/ARP Annual Meeting
Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review
Esteban Rubio¹, Alejandro Muñoz ¹ and Núria Casamira ², ¹Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, ²Medical Department, Gebro Pharma S.A., Barcelona, Spain
Background/Purpose: Methotrexate (MTX) is a commonly used drug for inflammatory joint diseases. Occasionally, its use has been associated with diffuse interstitial lung disease (DILD) development1. A…
Abstract Number: 370 • 2019 ACR/ARP Annual Meeting
Use of Serum Lung Injury Biomarkers for Predicting the Severity of Interstitial Lung Disease in Patients with Connective Tissue Disease Associated Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features
Sogol Amjadi¹, Tracy Frech ², Jessica Chan ³, Mary Beth Scholand ⁴, Troy Jaskowski ⁵, Sonia La’ulu ⁵, Jonathan Genzen ⁶, Dorota Lebiedz-Odrobina ⁷ and Ann Tebo ⁶, ¹University of Utah, Department of Internal Medicine, Division of Rheumatology, West Jordan, UT, ²Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ³University of Utah, Department of Radiology, salt lake city, UT, ⁴University of Utah, Department of Internal Medicine, Division of Pulmonary Medicine, salt lake city, UT, ⁵ARUP Institute for Clinical and Experimental Pathology, salt lake city, UT, ⁶ARUP Institute for Clinical and Experimental Pathology , University of Utah, Department of Pathology, salt lake city, UT, ⁷University of Utah, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Fibrotic lung diseases encompass a wide spectrum of clinical entities including connective tissue disease related interstitial lung disease (CTD-ILD) and interstitial pneumonia with autoimmune…
Abstract Number: 371 • 2019 ACR/ARP Annual Meeting
Role of Alternative Immunosuppressant Therapy in Management of Cardiac Sarcoidosis
Patil Injean¹, Yvonne Lee ² and Mehrnaz Hojjati ³, ¹Loma Linda University, Loma Linda, ²Loma Linda University Health, Loma Linda, ³Department of Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: Cardiac sarcoidosis (CS) is a rare, life-threatening disease and the second leading cause of death in patients with sarcoidosis. Currently, the recommended treatment for…
Abstract Number: 372 • 2019 ACR/ARP Annual Meeting
Periaortitis and Coronary Arteritis in IgG4-Related Disease: Eastern Mediterranean Experience
Gozde Kubra Yardımcı ¹, Alper Sarı ¹, Abdulsamet Erden ², Ertugrul Cagri Bolek ¹, Bayram Farisoğulları ¹, Levent Kilic ³, Berkan Armagan ⁴, Umut Kalyoncu ⁵, Tuncay Hazırolan ⁶, Ali İhsan Ertenli ¹ and Omer Karadag⁷, ¹Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ²Ministry of Health Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁴Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, ⁵Hacettepe University Department of Rheumatology, Ankara, Turkey, ⁶Hacettepe University, Division of Radiology, Ankara, ⁷Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey
Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory condition that may involve multiple organ systems. IgG4-RD can also lead to large vessel vasculitis and…
Abstract Number: 373 • 2019 ACR/ARP Annual Meeting
Prognostic Factors and Long-term Outcomes in Cardiac Sarcoidosis
Patrice Cacoub¹, Catherine Chapelon Abric ², Matthieu Resche-Rigon ³, David Saadoun ², Anne Desbois ² and Lucie Biard ³, ¹AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ²GHPS, Paris, France, ³Hôpital Saint Louis, Paris, France
Background/Purpose: To identify prognostic factors and to assess the effects of immunosuppressive drugs on relapse risk in patients presenting with cardiac sarcoidosis (CS).Methods: From a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].